Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kabrita is a goat milk-based infant formula developed by Ausnutria Hyproca B.V. It is designed as an alternative to cow milk-based formulas for infants aged 0-24 months, particularly those experiencing common gastrointestinal symptoms such as infantile colic, constipation, and diarrhea, as well as skin conditions like urticaria. The formula leverages the natural properties of goat milk, which contains a higher proportion of A2-type beta-casein and smaller fat globules compared to cow milk, potentially making it easier to digest and less allergenic for some infants. It is often enriched with prebiotic fibers such as galacto-oligosaccharides (GOS), unsaturated fatty acids (DHA/AA), and a specific fat blend (OPO) to mimic the composition of human milk and support gut health and microbiome development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kabrita.